Nivolumab for Recurrent or Metastatic Head and Neck Squamous Cell Carcinoma: A Retrospective Tertiary Centre’s Real-World Experience

Nivolumab for Recurrent or Metastatic Head and Neck Squamous Cell Carcinoma: A Retrospective Tertiary Centre’s Real-World Experience

Nivolumab, a PD-1 checkpoint inhibitor, was approved in Canada in 2017 for the treatment of recurrent or metastatic head and neck squamous cell carcinoma (R/M HNSCC) based on the phase 3 trial CHECKMATE-141. We aimed to examine the demographics and efficacy of nivolumab in a Canadian, real-world set...

Full description

Bibliographic Details
Main Authors: Yue (Jennifer) Du, Rui Fu, Justin T. Levinsky, Pabiththa Kamalraj, Kelvin K. W. Chan, Ambica Parmar, Antoine Eskander, Martin Smoragiewicz
Format: Article
Language:English
Published: MDPI AG 2023-09-01
Series:Current Oncology
Subjects:
nivolumab
head and neck
squamous cell carcinoma
cancer
chemotherapy
PD-1 checkpoint inhibitor
Online Access:https://www.mdpi.com/1718-7729/30/10/645

Internet

https://www.mdpi.com/1718-7729/30/10/645

Similar Items